09-28-01







Express Mail No. EL 853178302 US

↑AFFIX CUSTOMER NO. LAB

IN THE UNITED STATES PATENT ANDTRADEMARK OFFICE

UTILITY APPLICATION AND FEE TRANSMITTAL §(1.53(b))

Commissioner for Patents BOX PATENT APPLICATION Washington, D.C. 20231

Sir

Transmitted herewith for filing is the patent application of

Inventor(s) names and addresses:

- John N. Feder (1) 277 Dutchtown Zion Road Belle Mead, NJ 08502 United States of America
- (2) Gabe Mintier 318 Morrison Avenue Hightstown, NJ 08520 United States of America
- Chandra S. Ramanathan (3) 41 Alison Avenue Wallingford, CT 06492 United States of America
- (4) Donald R. Hawken 3223 Fieldcrest Court Lawrenceville, NJ 08648 United States of America
- Additional inventors are listed on a separate sheet

For: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR, HGPRBMY5, EXPRESSED HIGHLY IN BRAIN AND OVARIAN TISSUES

Enclos	osed Are:					
130 1 7 15	page(s) of specification page(s) of Abstract page(s) of claims sheets of ⊠ Formal ☐ Informal drawings page(s) of Declaration and Power of Attorney					
	 Unsigned Newly Executed Copy from prior application Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2) 					
	REQUEST AND CERTIFICATION UNDER 35 U.S.C. §122(b)(2)(B)(i) (form PTO/SB/35)					
	As indicated on the attached Request and Certification, Applicant(s) certify that the invention disclosed in the attached application HAS NOT and WILL NOT be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. Applicant(s) therefore request(s) that the attached application NOT be published under 35 U.S.C. §122(b).					
	Incorporation by Reference:					
	☐ The entire disclosure of the prior application, from which a copy of the combined Declaration and Power of Attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.					
	Deletion of Inventors (37 C.F.R. §1.63(d) and §1.33(b)					
	Signed statement attached deleting inventor(s) named in the prior application serial no, filed					
\boxtimes	Microfiche Computer Program (Appendix)					
	47 page(s) of Sequence Listing					
	 ☐ computer readable disk containing Sequence Listing ☐ Statement under 37 C.F.R. §1.821(f) that computer and paper copies of the Sequence Listing are the same 					
	Assignment Papers (assignment cover sheet and assignment documents)					
	A check in the amount of \$40.00 for recording the Assignment					
	Charge the Assignment Recordation Fee to Deposit Account No. <u>13-4500</u> , Order No.					
	Assignment Papers filed in the parent application Serial No.					
	Certification of chain of title pursuant to 37 C.F.R. §3.73(b)					

	Priority is claimed under 35 U.S.C. §119 for: Application No(s), filed, in (country).
	☐ Certified Copy of Priority Document(s) [] ☐ filed herewith
	filed in application Serial No, filed
	English translation document(s) []
	filed in application Serial No, filed
	Priority is claimed under 35 U.S.C. §119(e) for: Provisional Application No. 60/310,436, filed August 3, 2001; Provisional Application No. 60/306,605 filed July 19, 2001; Provisional Application No. 60/261,731 filed January 16, 2001; and Provisional Application No. 60/235,832 filed September 27, 2000.
	Information Disclosure Statement
	☐ Copy of [] cited references ☐ PTO Form-1449 ☐ References cited in parent application Serial No, filed
	Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)
	A copy of related pending U.S. Application(s) Serial No(s):, filed, respectively, is attached hereto.
	A copy of related pending U.S. Application(s) entitled,, filed to inventor(s), respectively, is attached hereto.
	A copy of each related application(s) was submitted in parent application serial no, filed
	Preliminary Amendment
\boxtimes	Return receipt postcard (MPEP 503)
	This is a continuation divisional continuation-in-part of prior application serial no, filed, to which priority under 35 U.S.C. §120 is claimed.
	☐ Cancel in this application original claims of the parent application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
	☐ A Preliminary Amendment is enclosed. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application).

		ition for Extension of Time and a Fee therefor has been or is being filed in arent application to extend the term for action in the parent application until							
	A copy	ent application							
	No Petition for Extension of Time and Fee therefor are necessary in the copending parent application.								
	Please abandon the parent application at a time while the parent application is pendin or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.								
	This is a		ivisional 🔲 contin	ation to this application e first line the sentence: ontinuation-in-part of co-pending					
I. CALCULATION OF APPLICATION FEE									
		Number Filed	Number Extra	Rate	Basic Fee \$710.00/355.00				
Total	Claims	41- 20 =	21	\$18.00/\$9.00	\$ 378.00				
Independent Claims		4- 3 =	1	\$80.00/ \$40.00	\$ 80.00				
⊠м	ultiple Depende	nt Claims	If marked, add fee of \$270.00 (\$135.00)		\$ 270.00				
	\$1,438.00								
	Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith \$								
\boxtimes	A check in the amount of \$1.438.00 in payment of the application filing fees is attached.								
	Charge fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.								

The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, including all extension of time fees pursuant to 37 C.F.R. § 1.17 for maintaining copendency with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3053-4118US3. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted, MORGAN & FINNEGAN, L.L.P.

Dated: September 26, 2001

By: Nestie A. Serunian

Registration No. 35,353

Sender's Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone (212) 751-6849 Facsimile

Correspondence Address:

BRISTOL-MYERS SQUIBB COMPANY Route 206 and Provinceline Road Princeton, NJ 08540

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : FEDER, J. et al.

Group Art Unit: To Be Assigned

Serial No.

To be Assigned

Examiner: To Be Assigned

Filed

September 26, 2001

For

A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR, HGPRBMY5,

EXPRESSED HIGHLY IN BRAIN AND OVARIAN TISSUES

EXPRESS MAIL CERTIFICATE

Express Mail Label No. EL 853178302 US

Date of Deposit September 26, 2001

I hereby certify that the following attached paper(s) or fee

Utility Application and Fee Transmittal (1.53(b));

- Specification (130 pages); claims (number of claims: 34 7 pages), Abstract (1 page), Drawings (15 sheets formal drawings Figures 1-12),
- Paper Copy of Sequence Listing (47 pages);
- 1 computer disk containing Sequence Listing;
- Statement Under 37 C.F.R. §1.821(f);
- 6. Check in the amount of \$1,438.00; and
- Return Postcard.

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, BOX PATENT APPLICATION, Washington, D.C. 20231.

Jesus R. Remedios

(Typed or printed name of person mailing

paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Sender's Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone (212) 751-6849 Facsimile Correspondence Address:

BRISTOL-MYERS SQUIBB COMPANY Route 206 and Provinceline Road

Princeton, NJ 08540

9 15 4

M&F: 3053-4118US3

Docket No. D0041NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :

FEDER, J. et al.

Serial No.

To be assigned

Group Unit: To be assigned

Filed

September 26, 2001

Examiner : To be assigned.

For

A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,

HGPRBMY5, EXPRESSED HIGHLY IN BRAIN AND OVARIAN

TISSUES

Statement Under 37 C.F.R. §1.821(f) or §1.825(b)

Commissioner of Patents Washington, D.C. 20231

Dear Sir:

I hereby certify that:

[X] The paper Sequence Listing submitted herewith and computer readable Sequence Listing attached hereto are identical (37 C.F.R. §1.821(f)).

 The substitute paper Sequence Listing and substitute computer readable Sequence Listing submitted herewith are identical. No new matter is included (37 C.F.R. \$1.825(b)).

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Date: September 26, 2001

Bv:

Leslie A. Sermian

Reg. No. 35,353

Sender's Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone (212) 751-6849 Facsimile Correspondence Address:

BRISTOL-MYERS SQUIBB COMPANY Route 206 and Provinceline Road

Princeton, NJ 08540